A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study

Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Alba Bigoloni, Luca Fumagalli, Nicola Gianotti, Silvia Nozza, Davide Ferrari, Massimo Locatelli, Adriano Lazzarin, Antonella Castagna

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)477-479
Number of pages3
JournalDrug Design, Development and Therapy
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this